What the FDA labels say about taking them together
Bevacizumab and bevacizumab-maly
Bevacizumab-maly's FDA label of January 27, 2026 names bevacizumab in its drug interactions section; the bevacizumab labels PlainMeds reads (4) do not name bevacizumab-maly. The bevacizumab-maly label: “Advise females of the potential risk. Congestive Heart Failure (CHF): Discontinue Alymsys in patients who develop CHF.”
Check it at the source: the bevacizumab FDA label on DailyMed (effective March 23, 2026, Amneal Pharmaceuticals LLC); the bevacizumab-maly FDA label on DailyMed (effective January 27, 2026, Valorum Biologics, LLC).
What does the bevacizumab label say about bevacizumab-maly?
Bevacizumab's label (effective March 23, 2026) and its 3 other brand-application labels do not name bevacizumab-maly in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ALYMSYS), Amneal Pharmaceuticals LLC, effective March 23, 2026 (SPL set 6b4040a2-a5c5-4ff0-ab45-935d7e49cf78), via openFDA; the full label on DailyMed
What does the bevacizumab-maly label say about bevacizumab?
Bevacizumab-maly label, drug interactionsDRUG INTERACTIONS Effects of Alymsys on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; however, 3 of the 8 patients receiving bevacizumab with paclitaxel and carboplatin had lower paclitaxel exposure after four cycles of treatment (at Day 63) than those at Day 0, while patients receiving paclitaxel and carboplatin alone had a greater paclitaxel exposure at Day 63 than at Day 0.
Bevacizumab-maly label, warnings and precautionsAdvise females of the potential risk. (5.11, 8.3) Congestive Heart Failure (CHF): Discontinue Alymsys in patients who develop CHF.
Source: FDA drug label (ALYMSYS), BLA761231 (Amneal Pharms Llc), as published by Valorum Biologics, LLC, effective January 27, 2026 (SPL set 42b4f96e-1f70-2126-e063-6294a90a93e3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Bevacizumab | Bevacizumab-maly | |
|---|---|---|
| Labeled for | Colorectal cancer, Lung cancer | Colorectal cancer, Lung cancer |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once